BRAWO - breast cancer treatment with Afinitor® (Everolimus) and exemestane for ER plus women

被引：0
|
作者：
Schuetz, F. [1 ]
Jackisch, C. [2 ]
Tesch, H. [3 ]
Bloch, W. [4 ]
Muth, M. [5 ]
Kreuzeder, J. [5 ]
Lueftner, D. [6 ]
机构：
[1] Univ Hosp, Dept Gynecol & Obstet, Heidelberg, Germany
[2] Klinikum Offenbach GmbH, Dept Obstet & Gynecol, Offenbach, Germany
[3] Onkol Bethanien, Frankfurt, Germany
[4] German Sport Univ Cologne, Inst Cardiovasc Res & Sport Med, Cologne, Germany
[5] Novartis Pharma GmbH, Nurnberg, Germany
[6] Div Hematol Oncol & Tumor Immunol Charite, Med Dept, Berlin, Germany
来源：
ONKOLOGIE | 2013年 / 36卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：158 / 159
页数：2
相关论文
共 50 条
  • [1] Results of the 3rd interim analysis of BRAWO - breast cancer treatment with everolimus and exemestane for ER plus women
    Tesch, H.
    Grischke, E-M
    Fasching, P.
    Decker, T.
    Uleer, C.
    Schneeweiss, A.
    Foerster, F.
    Wimberger, P.
    Kluth-Pepper, B.
    Schubert, J.
    Bloch, W.
    Jackisch, C.
    Schuetz, F.
    Lueftner, D.
    [J]. Oncology Research and Treatment, 2015, 38 : 252 - 253
  • [2] Breast cancer treatment with everolimus and exemestane for ER plus women: Results of the first interim analysis of the noninterventional trial BRAWO
    Lueftner, Diana
    Schuetz, Florian
    Grischke, Eva-Maria
    Fasching, Peter A.
    Wimberger, Pauline
    Foerster, Frank Gerhard
    Decker, Thomas
    Uleer, Christoph
    Muth, Mathias
    Kreuzeder, Julia
    Bloch, Wilhelm
    Tesch, Hans
    Jackisch, Christian
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [3] Economic evaluation of everolimus plus exemestane versus bevacizumab plus paclitaxel and bavacizumab plus eapecitabine for the management of postmenopausal women with ER breast cancer
    Kourlaba, Georgia
    Rapti, Vasiliki
    Alexopoulos, Athanasios
    Relakis, John
    Koumakis, Georgios
    Chatzikou, Magdalini
    Manladakis, Mikolaos
    Georgoullas, Vassilis
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [4] Subgroup analysis on efficacy in the routine treatment - Results of the 2nd interim analysis of BRAWO, the non-interventional trial "Breast Cancer Treatment with Everolimus and Exemestane for HR plus Women"
    Jackisch, Christian
    Grischke, Eva-Maria
    Schneeweiss, Andreas
    Decker, Thomas
    Uleer, Christoph
    Foerster, Frank
    Tome, Oliver
    Wimberger, Pauline
    Kurbacher, Christian M.
    Mueller, Bettina
    Harbeck, Nadia
    Mundhenke, Christoph
    Kuemmel, Sherko
    Muth, Mathias
    Kreuzeder, Julia
    Bloch, Wilhelm
    Tesch, Hans
    Lueftner, Diana
    Schuetz, Florian
    Fasching, Peter A.
    [J]. CANCER RESEARCH, 2015, 75
  • [5] EVEROLIMUS PLUS EXEMESTANE COMPARED TO EXEMESTANE AND FULVESTRANT FOR THE TREATMENT OF ER+HER2-METASTASTIC BREAST CANCER IN THE UNITED KINGDOM - A SOCIETAL PERSPECTIVE
    Polanyi, Z.
    Dale, P.
    Taylor, M.
    Lewis, L.
    Glanville, J.
    Vieira, J.
    Chandiwana, D.
    [J]. VALUE IN HEALTH, 2014, 17 (07) : A632 - A632
  • [6] Impact of physical activity/exercise on adverse events and quality of life during treatment with everolimus and exemestane for ER plus women - Results of the 3rd interim analysis of BRAWO
    Bloch, W.
    Baumann, F.
    Zimmer, P.
    Grischke, E-M
    Fasching, P. A.
    Decker, T.
    Uleer, C.
    Schneeweiss, A.
    Salat, C.
    Wimberger, P.
    Mundhenke, C.
    Foerster, F.
    Kluth-Pepper, B.
    Schubert, J.
    Tesch, H.
    Schuetz, F.
    Lueftner, D.
    Jackisch, C.
    [J]. CANCER RESEARCH, 2016, 76
  • [7] Everolimus plus exemestane for HR plus advanced breast cancer in routine clinical practice-Final results from the non-interventional trial, BRAWO
    Lueftner, D.
    Schuetz, F.
    Schneeweiss, A.
    Grischke, E-M
    Bloch, W.
    Decker, T.
    Uleer, C.
    Salat, C.
    Foerster, F.
    Schmidt, M.
    Mundhenke, C.
    Tesch, H.
    Jackisch, C.
    Fischer, T.
    Guderian, G.
    Hanson, S.
    Fasching, P.
    [J]. CANCER RESEARCH, 2019, 79 (04)
  • [8] A COST-UTILITY ANALYSIS OF EVEROLIMUS PLUS EXEMESTANE FOR THE TREATMENT OF ER+HER2-METASTATIC BREAST CANCER IN THE UNITED KINGDOM
    Taylor, M.
    Lewis, L.
    Vieira, J.
    Chandiwana, D.
    [J]. VALUE IN HEALTH, 2013, 16 (07) : A416 - A416
  • [9] EVEROLIMUS PLUS EXEMESTANE VERSUS EVEROLIMUS OR CAPECITABINE MONOTHERAPY IN BREAST CANCER: BOLERO-6
    Ejlertsen, B.
    Jerusalem, G.
    Hurvitz, S.
    De Boer, R.
    Taran, T.
    Sahmoud, T.
    Burris, H.
    [J]. BREAST, 2013, 22 : S109 - S109
  • [10] Incidence and management of toxicities associated with everolimus and exemestane (EVE plus EXE) in ER plus advanced breast cancer: The Royal Marsden experience
    Thanopoulou, E.
    Omarini, C.
    Patwari, S.
    Allen, M.
    Smith, I. E.
    Parton, M.
    O'Brien, M.
    Turner, N.
    Johnston, S. R. D.
    [J]. EUROPEAN JOURNAL OF CANCER, 2014, 50 : S180 - S181
12345